LOBE Lobe Sciences Ltd.
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Lobe Sciences (CNSX: LOBE)
›
Lobe Sciences (CNSX: LOBE) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0500 CAD on 19 November 2026, up 11.1% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.1800 CAD: the price is 72.2% below the high and 66.7% above the low.
Its market capitalisation is 15.41M CAD.
Lobe Sciences reports return on equity of -187.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.87M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.